Harvard Bioscience Q2 revenue rises on telemetry demand, lifts 2026 outlook
HBIO•Q2 results
Harvard Bioscience said second-quarter revenue grew 11% year over year to $22.7 million, reflecting stronger demand and an improved environment across key customer channels, according to CEO John Duke.
Adjusted EBITDA for the quarter rose to $1.7 million from $1.5 million a year earlier. The company reported a Q2 net loss of $2.91 million.
Drivers of growth
The company cited solid commercial traction in telemetry and cellular and molecular technology products, driven by its AAA and electroporation businesses.
It also said outperformance in CMT products and China contributed to a slight mix impact on adjusted gross margin.
Outlook and analyst view
Harvard Bioscience sees third-quarter revenue of $21.0 million to $22.6 million.
The company raised its full-year 2026 revenue growth guidance to 3% to 5% year over year and expects 2026 adjusted gross margin of 57% to 59%.
The current average analyst rating on the shares is buy, with one strong buy or buy, one hold and no sell or strong sell ratings. The median 12-month price target is $6.00, about the stock's August 10 close of .
